ATE249215T1 - Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose - Google Patents

Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose

Info

Publication number
ATE249215T1
ATE249215T1 AT93901204T AT93901204T ATE249215T1 AT E249215 T1 ATE249215 T1 AT E249215T1 AT 93901204 T AT93901204 T AT 93901204T AT 93901204 T AT93901204 T AT 93901204T AT E249215 T1 ATE249215 T1 AT E249215T1
Authority
AT
Austria
Prior art keywords
app
amyloidosis
modulators
medication
produce
Prior art date
Application number
AT93901204T
Other languages
English (en)
Inventor
Samuel E Gandy
Gregg L Caporaso
Paul Greengard
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Application granted granted Critical
Publication of ATE249215T1 publication Critical patent/ATE249215T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Basic Packing Technique (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AT93901204T 1991-12-17 1992-12-17 Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose ATE249215T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/809,174 US5242932A (en) 1991-12-17 1991-12-17 Treatment of amyloidosis associated with alzheimer disease
PCT/US1992/010961 WO1993011762A1 (en) 1991-12-17 1992-12-17 Use of app modulators for the manufacture of a medicament for the treatment of amyloidosis

Publications (1)

Publication Number Publication Date
ATE249215T1 true ATE249215T1 (de) 2003-09-15

Family

ID=25200707

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93901204T ATE249215T1 (de) 1991-12-17 1992-12-17 Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose

Country Status (8)

Country Link
US (2) US5242932A (de)
EP (1) EP0617619B1 (de)
JP (1) JPH07501554A (de)
AT (1) ATE249215T1 (de)
AU (1) AU678159B2 (de)
CA (1) CA2126083C (de)
DE (1) DE69233195T2 (de)
WO (1) WO1993011762A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
WO1994017056A1 (en) * 1993-01-27 1994-08-04 Ariad Pharmaceuticals, Inc. Lactones and their pharmaceutical applications
WO1994022437A2 (en) * 1993-03-29 1994-10-13 Queen's University At Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
WO1995009236A1 (en) * 1993-09-28 1995-04-06 The General Hospital Corporation USING ANTISENSE OLIGONUCLEOTIDES TO MODULATE NERVE GROWTH AND TO REVERSE β/A4 AMYLOID-INDUCED MORPHOLOGY
AU1831195A (en) * 1994-01-13 1995-08-01 Research Foundation For Mental Hygiene, Inc. Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
AU692237B2 (en) * 1994-02-03 1998-06-04 Picower Institute For Medical Research, The Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5523295A (en) * 1994-07-06 1996-06-04 Brandeis University Method for treating and preventing alzheimer's disease
US6365414B1 (en) * 1994-08-26 2002-04-02 The General Hospital Corporation Vitro system for determining formation of Aβ amyloid
AU703667B2 (en) * 1994-09-20 1999-04-01 Regents Of The University Of California, The Drugs to improve synaptic transmission
US5972634A (en) 1994-10-19 1999-10-26 The General Hospital Corporation Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
CA2221684A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043256A (en) * 1996-09-16 2000-03-28 Grassetti; Davide R. Antimutagenic agents
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US6071493A (en) 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
JP2001512422A (ja) * 1997-02-05 2001-08-21 アレリツクス・フアーム−エコ・エル・ピー 記憶増強のための薬剤
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
WO1999001118A2 (en) * 1997-07-01 1999-01-14 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
AU9125798A (en) * 1997-08-28 1999-03-16 University Of Washington Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6767898B2 (en) * 1998-08-28 2004-07-27 University Of Washington Methods for using specific saccharides for treating alzheimer's disease and other amyloidoses
JP2002525268A (ja) * 1998-09-16 2002-08-13 オンコファーマシューティカル， インコーポレイテッド ゴルジ装置妨害剤の注射可能な処方物での腫瘍学的腫瘍の処置
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
IL146143A0 (en) * 1999-04-28 2002-07-25 Univ Kingston Compositions and methods for treating amyloidosis
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
AU2001296558A1 (en) 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2002254029A1 (en) 2001-02-27 2002-09-12 Daniel L. Alkon Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
US6664520B2 (en) * 2001-05-21 2003-12-16 Thermal Solutions, Inc. Thermal seat and thermal device dispensing and vending system employing RFID-based induction heating devices
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20090030055A1 (en) * 2002-07-02 2009-01-29 Thomas Nelson PKC activation as a means for enhancing sAPPALPHA secretion and improving cognition using bryostatin type compounds
CA2499170A1 (en) * 2002-09-27 2004-04-08 Children's Medical Center Corporation Methods and compositions for treatment of neurological disorder
US7595308B2 (en) * 2002-11-18 2009-09-29 Grenpharma Llc Compositions for treating and/or preventing diseases characterized by the presence of metal ions
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
WO2005016196A1 (en) * 2003-08-04 2005-02-24 Trustees Of Dartmouth College Compositions and methods for destabilizing lysosomes to increase oncogenic or aberrant protein degradation
AU2005299474A1 (en) * 2004-10-22 2006-05-04 Grenpharama Llc Compositions for treating and/or preventing diseases characterized by the presence of the metal ions
EP1828111A2 (de) * 2004-11-12 2007-09-05 Neurochem (International) Limited Verfahren und fluorierte zusammensetzungen zur behandlung von amyloidbedingten krankheiten
CA2582270A1 (en) * 2004-11-15 2006-05-26 Blanchette Rockefeller Neurosciences Institute Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer's disease
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
BRPI0519243A2 (pt) * 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US20070054890A1 (en) * 2005-07-29 2007-03-08 Alkon Daniel L Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
US20090029873A1 (en) * 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
MX2008008213A (es) * 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
CN1991364A (zh) 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
DK2089417T3 (en) 2006-10-12 2015-03-23 Bhi Ltd Partnership Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid
CN101730529A (zh) * 2006-12-22 2010-06-09 贝鲁斯健康(国际)有限公司 用于治疗代谢疾病和糖尿病的方法、化合物和组合物
US20090155352A1 (en) * 2007-11-20 2009-06-18 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
CA2731171C (en) 2008-07-28 2016-10-18 Blanchette Rockefeller Neurosciences Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
EP2669386A1 (de) * 2008-07-28 2013-12-04 Blanchette Rockefeller Neurosciences Institute Stimulierte ausgelöste genomische Profilmarker von Morbus Alzheimer
EP2419100A4 (de) * 2009-04-14 2013-07-17 Kim Nicholas Green Verfahren zur senkung der pro-adam10-sekretase- und/oder beta-sekretase-konzentration
CN102573839A (zh) * 2009-05-11 2012-07-11 加利福尼亚大学董事会 降低泛素化蛋白水平的方法
EP2483684B1 (de) * 2009-10-02 2018-04-18 Blanchette Rockefeller Neurosciences, Institute Fibroblast wachstumsmuster zur diagnose der alzheimer-krankheit
EP2483695A2 (de) * 2009-10-02 2012-08-08 Blanchette Rockefeller Neurosciences, Institute Unnormale änderungen der verarbeitung von pkc-isozymen in morbus-alzheimer-peripherzellen
EP2513062A1 (de) * 2009-12-16 2012-10-24 Institut National de la Santé et de la Recherche Médicale 7-chlor-chinolin-4-aminverbindungen und ihre verwendung zur prävention oder behandlung von erkrankungen mit der manifestation von amyloidplaquebildung und/oder einer dysfunktion des app-metabolismus
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
CN103492415B (zh) * 2011-01-07 2017-12-29 精工爱普生株式会社 针对淀粉状蛋白前体蛋白质的信号肽的抗体
EP2780316B1 (de) 2011-11-13 2020-04-15 Blanchette Rockefeller Neurosciences Institute Ester von dcpla und behandlungsverfahren damit
WO2013180011A1 (ja) 2012-05-28 2013-12-05 東亞合成株式会社 抗菌ペプチド及びその利用
JP6311935B2 (ja) 2012-10-18 2018-04-18 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806537A (en) * 1987-04-16 1989-02-21 City Of Hope Use of amodiaquin and related compounds in treatment of nervous system degeneration
CA2011086A1 (en) * 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
US4916135A (en) * 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5093333A (en) * 1991-04-29 1992-03-03 American Home Products Corporation N-substituted-2-aminoquinolines useful for treating hypofunction of the cholinergic system

Also Published As

Publication number Publication date
DE69233195T2 (de) 2004-04-01
JPH07501554A (ja) 1995-02-16
US5242932A (en) 1993-09-07
AU4035793A (en) 1993-07-19
EP0617619B1 (de) 2003-09-10
CA2126083C (en) 2004-06-15
US5348963A (en) 1994-09-20
EP0617619A1 (de) 1994-10-05
DE69233195D1 (de) 2003-10-16
AU678159B2 (en) 1997-05-22
WO1993011762A1 (en) 1993-06-24
CA2126083A1 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
ATE249215T1 (de) Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose
ATE180408T1 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
FI893433A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
ATE217754T1 (de) Verwendung von aerogelen in der landwirtschaft
NO924433L (no) Isoksazol-4-karboksylsyreamider og hydroksyalkyliden-cyaneddiksyreamider, legemidler inneholdende disse forbindelsene og deres anvendelse
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ATE413386T1 (de) Ppar-gamma modulatoren
ATE94387T1 (de) Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung.
ATE126433T1 (de) Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen.
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69429078D1 (de) Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
ATE169820T1 (de) Verwendung eines bakteriziden/die permeabilität erhöhenden proteins oder von biologisch aktiven analogen davon zur herstellung eines arzneimittels zur behandlung von endotoxin- assoziierten storungen
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
KR900004256A (ko) 살균제
ATE175112T1 (de) Verwendung von taurin zur herstellung eines medikaments zur stimulierung der myeloperoxidaseaktivität
ATE258791T1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ES483661A1 (es) Procedimiento para la obtencion de derivados de 1,4-dihidro-piridina sila-sustituidos
DE3688528D1 (de) Optische analoge datenverarbeitungsanordnungen zur behandlung von bipolaren und komplexen daten.
ATE11217T1 (de) Antibiotische substanzen, verfahren zu deren herstellung und deren zusammensetzungen; stamm von staphylococcus epidermidis, welcher diese antibiotische substanz produziert und deren zusammensetzungen.
DK160316C (da) Analogifremgangsmaade til fremstilling af beta-casomorphinanaloge peptider samt pharmakologisk acceptable syreadditionssalte og metalkomplekser deraf
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ES433860A1 (es) Procedimiento de preparacion de derivados del acido ciclo- pentano-carboxilico.
DE69221725D1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties